227963-57-7

Usage

Uses

Used in Pharmaceutical Synthesis:
ETHYL 3-(2-AMINO-5-BROMOPYRIDIN-3-YL)ACRYLATE is used as a key intermediate in the synthesis of pharmaceuticals for its unique reactivity and structural properties that contribute to the development of new drugs.
Used in Organic Compound Synthesis:
In the field of organic chemistry, ETHYL 3-(2-AMINO-5-BROMOPYRIDIN-3-YL)ACRYLATE is utilized as a building block for the creation of complex organic molecules, leveraging its specific chemical characteristics.
Used in Biotechnology Research:
ETHYL 3-(2-AMINO-5-BROMOPYRIDIN-3-YL)ACRYLATE is employed in biotechnological research to explore its potential biological activity, with the aim of discovering new applications in medicine and other related fields.
Used in Medicinal Chemistry:
In medicinal chemistry, ETHYL 3-(2-AMINO-5-BROMOPYRIDIN-3-YL)ACRYLATE is used as a precursor or a modifier in the design and synthesis of new pharmaceutical agents, potentially leading to advancements in drug discovery and development.

InChI:InChI=1/C10H12N2O2/c1-2-14-10(13)6-4-8-3-5-9(11)12-7-8/h3-7H,2H2,1H3,(H2,11,12)/b6-4+

Upstream product

• 69879-22-7 6-amino-3-pyridinecarbaldehyde 
• 1072-97-5 5-bromo-2-pyridylamine 
• 140-88-5 ethyl acrylate 

Downstream Products

• 910823-54-0 3-[3-(benzo[1,3]dioxol-5-ylamino)-2-phenethyl-imidazo[1,2-a]pyridin-6-yl]-acrylic acid ethyl ester 

Relevant academic research and scientific papers

Imidazolylamide derivative

The present invention pertains to an imidazolylamide derivative represented by formula (1) that exhibits an exceptional suppressive effect on cancer cell sphere formation ability and that is useful as an antitumor agent that can be administered orally, or a pharmacologically acceptable salt thereof. [In the formula, ring Q1 represents a C6-10 aryl group or the like; m represents 0, 1, 2, 3, 4, or 5; R3, independently when multiple, represent(s) a halogen atom or the like; R1 and R2 independently represent a hydrogen atom or the like; W1 represents a C1-4 alkylene group (said group may be substituted by 1-3 fluorine atoms or C3-7 cycloalkyls); W2 represents —NR4aC(O)— or the like (where R4a represents a hydrogen atom or C1-6 alkyl group); and ring Q2 represents a C6-10 arylgroup or the like]

Aminoheteroaryl benzamides as kinase inhibitors

The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.

IMIDAZO[1,2-A]PYRIDINE DERIVATIVES: PREPARATION AND PHARMACEUTICAL APPLICATIONS

The present invention relates to hydroxamate compounds which are inhibitors of histone deacetylase. More particularly, the present invention relates to imidazo[1,2-a]pyridine containing compounds and methods for their preparation. These compounds may be u

Substituted anilides

The invention is directed to physiologically active compounds of formula (I): wherein: R1is hydrogen, halogen, hydroxy, lower alkyl or lower alkoxy; X1, X2and X6independently represent N or CR10; and one of X3, X4and X5represents CR11and the others independently represents N or CR10; where R10is hydrogen, amino, halogen, hydroxy, lower alkyl, lower alkoxy, lower alkylthio, lower alkylsulphinyl, lower alkylsulphonyl, nitro or trifluoromethyl; and R11represents a group —L1—Ar1—L2—Y; and the corresponding N-oxides, and their prodrugs; and pharmaceutically acceptable salts and solvates of such compounds and their N-oxides and prodrugs. Such compounds have valuable pharmaceutical properties, in particular the ability to regulate the interaction of VCAM-1 and fibronectin with the integrin VLA-4 (α4β1).